Committed to a world WITHOUT Alzheimer’s disease.

Alzheimer’s Therapeutic Research Institute

We are dedicated to helping the nation and the world confront the problem of Alzheimer’s Disease (AD) by rigorously testing novel treatments and identifying reliable markers for early detection of the disease.

Our Impact

We lead the way in AD research

We develop the deepest understanding of the disease and all its stages.

Sara in ATRI Lab 2022

We develop and hone the right tools for studying therapeutics.

We create rigorous trial designs and analytical approaches.

Take Action

How YOU Can Make an Impact

Here at ATRI we rely on our community to make a difference when it comes to advancing AD research. You can help be a part of that, whether through direct participation or supporting the Institute.

We lead scientific advancements & understanding of Alzheimer’s disease.

Dr. Alois Alzheimer describes disease

Alzheimer’s Disease Cooperative Study (ADCS) launched. Funded by NIA and led by Leon Thal

Anti-Amyloid Treatment in Asymptomatic Alzheimer's study

ATRI founded as a San Diego Institute of USC

Alzheimer’s Clinical Trials Consortium (ACTC) formed. Funded by NIA and led by Aisen, Petersen and Sperling.

Aducanumab receives accelerated approval for treatment of Alzheimer’s disease

Founding director of USC ATRI

Read the Publications

Paul Aisen, MD

Contribution of Alzheimer’s biomarkers and risk factors to cognitive impairment and decline across the Alzheimer’s disease continuum
Using the Alzheimer’s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer’s disease

The case for low-level BACE1 inhibition for the prevention of Alzheimer’s disease